Clinical Trial Update: Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety study of the monoclonal antibody mogamulizumab (KW-0761) in subjects with peripheral T-cell lymphoma has completed, with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Poteligeo (mogamulizumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Peripheral T-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-29